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protective (proliferative) and destructive (apoptotic)
mechanisms. Thus, natural occurring autoantibodies
may stimulate or inhibit apoptosis by interfering with
Bcl-2 proteins or with the large family of transmem-
brane receptors. This theoretical concept is convincingly
backed up by recent ﬁndings that UDCA can prevent
apoptosis by reducing the apoptotic threshold through
modulation of the classical mitochondrial pathway [13].
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We read with interest the paper byMehta et al. [1] that
reported that due to imperfection of liver biopsy as a ref-
erence standard it is not possible to estimate the accuracy
of a non-invasive test for the diagnosis of liver ﬁbrosis.
However, we would like to challenge some points raised.
Diagnosis cannot be regarded as a primary outcome
but alternatively can be represented as a decisional node.
The identiﬁcation and staging of a disease (diagnosis)
should support the decision to treat a patient or not. The
utility of diagnosis derives from the beneﬁts of this deci-
sion. Thus, in the context of liver disease, patients with
severe ﬁbrosis have a worse prognosis and those with
signiﬁcant ﬁbrosis fare better with treatment. The iden-
tiﬁcation of these subgroups is useful and allows the def-
inition of their prognosis and initiation of eﬀective
treatment, but these diﬀerences in prognosis and beneﬁts
of treatment have widely been evaluated using exclu-
sively histological deﬁnition, even if imperfect. Actually,
no diagnostic test can be regarded as perfect and thus
there are no longer ‘‘gold” but only reference standards.
The limitations of liver biopsy are well known; the most
important being the high percentage of false-negative
results yielded in the cases of signiﬁcant or severe
ﬁbrosis.In the study by Mehta et al. there is an implicit
assumption that the prognosis and the response to treat-
ment in patients with false-negative results at histology
are actually the same as in those with true-positive
results. This assumption has still to be unequivocally
proved. So far, it has not been possible to assume that
non-invasive ﬁbromarkers are more useful only for the
merit of reducing the false- negative rate of histology.
In fact, only the assessment of the prognosis of patients
with discrepant results (between histology and ﬁbromar-
kers) could deﬁne their actual advantage.
An unequivocal demonstration would entail a ran-
domized controlled trial comparing hard clinical out-
comes in patients in which the diagnosis of signiﬁcant
or severe ﬁbrosis was obtained either by histology or
by non-invasive ﬁbromarkers.
Furthermore, the analysis by Mehta et al. is limited to
the overall accuracy and AUC assessment: these are two
diagnostic measures of true results, but no information
can be derived on false-positive or -negative results.
However, the clinical utility of a diagnostic test depends
on false-negative and positive rate (i.e. on sensitivity and
speciﬁcity).
Finally, Mehta et al. [1] seem to conceive possible
alternatives to liver biopsy only in the form of a sin-
gle test. In our opinion, the choice of a diagnostic
strategy comprising sequential tests (conditionally
independent) [2,3] with diﬀerent operative characteris-
tics may be more eﬀective. For the diagnosis of ﬁbro-
sis, a diagnostic ﬂow chart can be designed using an
initial highly sensitive test to rule out the diagnosis
if negative and if positive followed by more speciﬁc
tests to conﬁrm it.
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To the Editor:
Drs. Colli and Fraquelli underscore several important
implications of our analysis of non-invasive liver ﬁbrosis
test validity [1,2]. The central ﬁnding is that limitations
in the validity of an imperfect gold standard obviate pre-
cise characterization of the validity of surrogates. When
applied to the liver biopsy, our calculations demonstrate
that a perfect marker of liver ﬁbrosis could not be distin-
guished from what many consider to be a clinically
unacceptable one, unless the biopsy sensitivity and spec-
iﬁcity are above 90%. The degree to which error in the
biopsy might aﬀect the apparent validity of a surrogate
should always be considered in non-invasive marker
research.
Drs. Colli and Fraquelli make an excellent observa-
tion about the use of test results in medical management.
Clinicians interpret a single test result in light of the out-
come of other tests, their intrinsic validities, the pre-test
probability of the condition, and many other consider-
ations. Our study does not address the integration of
these multiple factors but rather the simple interpreta-
tion of a substitute for a single test. A logical extension
of our study would be to assess the performance of
multiple diagnostic tests (e.g., serum marker panel and
elastography). In addition, liver biopsy provides infor-
mation on other factors like steatosis that cannot be
ascertained from some non-invasive surrogates, and
our computations do not account for these added diag-
nostic beneﬁts. Likewise, Drs. Colli and Fraquelli cor-
rectly point out that our data showing the limitations
in the traditional way that surrogate markers are evalu-
ated does not answer the pressing clinical question of
what to do when there is a diﬀerence. Fortunately,
non-invasive markers are increasingly being assessed in
clinical trials of hepatitis C treatment. Results of these
studies, and others employing alternative ‘gold stan-
dards’ like the natural history of disease, will be neces-
sary to improve our use of pre-treatment testing to
manage patients with chronic hepatitis C.
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